our pipeline pipeline chart therapeutic vaccines tg4010 tg4001 tg1050 oncolytic viruses pexa vec tg6002 collaborations publications business development strategy meetings investor relations dashboard financial information key figures financial reports regulated information stock information general funding history stock price shareholder structure analysts investor events & presentations corporate presentation financial calendar webcasts investor events corporate governance annual general meeting information request media press releases media interviews home about us overview our people management committee board of directors qualified pharmacist careers our history subsidiaries and holdings our pipeline pipeline chart therapeutic vaccines tg4010 tg4001 tg1050 oncolytic viruses pexa vec tg6002 collaborations publications business development strategy meetings investor relations dashboard financial information key figures financial reports regulated information stock information general funding history stock price shareholder structure analysts investor events & presentations corporate presentation financial calendar webcasts investor events corporate governance annual general meeting information request media press releases media interviews homepageadmin2015 11 05t11 12 16 00 00 immunotherapies for cancer and infectious diseases transgene euronext tng part of institut m rieux is a publicly traded french biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases . latest news october 11 2016 transgene announces collaboration with merck and pfizer to evaluate the combination of tg4001 with avelumab in hpv positive head & neck cancer in a phase 1 2 study october 5 2016 transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines september 5 2016 transgene provides an update on its development strategy and on its first half year 2016 financials september 1 2016 transgene announces participation at upcoming investor events contacts careers glossary contacts carri res glossaire transgene sa 400 boulevard gonthier d andernach parc d innovation cs8016667405 illkirch graffenstaden cedex francetel . 33 0 3 88 27 91 00 fax . 33 0 3 88 27 91 11 2016 transgene all rights reservedtous droits r serv sterms of use creditsmentions l gales cr dits